VistaGen Therapeutics, Inc.VTGNNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank59
3Y CAGR-61.5%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-61.5%/yr
vs +42.3%/yr prior
Acceleration
-103.8pp
Decelerating
Percentile
P59
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.53% |
| Q3 2025 | -26.89% |
| Q2 2025 | -9.03% |
| Q1 2025 | 4.13% |
| Q4 2024 | -6.28% |
| Q3 2024 | -17.28% |
| Q2 2024 | -6.80% |
| Q1 2024 | -44.08% |
| Q4 2023 | -16.28% |
| Q3 2023 | 3.12% |
| Q2 2023 | 42.82% |
| Q1 2023 | -25.32% |
| Q4 2022 | 44.16% |
| Q3 2022 | 11.55% |
| Q2 2022 | -18.45% |
| Q1 2022 | -58.37% |
| Q4 2021 | 17.65% |
| Q3 2021 | -65.24% |
| Q2 2021 | -24.56% |
| Q1 2021 | -17.36% |
| Q4 2020 | -60.89% |
| Q3 2020 | -5.51% |
| Q2 2020 | 4.34% |
| Q1 2020 | 45.27% |
| Q4 2019 | -11.43% |
| Q3 2019 | 14.02% |
| Q2 2019 | -8.78% |
| Q1 2019 | 20.44% |
| Q4 2018 | 3.23% |
| Q3 2018 | -76.53% |
| Q2 2018 | -3.25% |
| Q1 2018 | -42.19% |
| Q4 2017 | 42.57% |
| Q3 2017 | -120.91% |
| Q2 2017 | 11.28% |
| Q1 2017 | 3.40% |
| Q4 2016 | 14.91% |
| Q3 2016 | -57.88% |
| Q2 2016 | 76.90% |
| Q1 2016 | -296.90% |